Abstract
Rhinovirus is the most common trigger for asthma exacerbations and causes neutrophilic inflammation. Neutrophilic inflammation and airway mucus in asthma exacerbations are often resistant to effects of glucocorticoids, and there are no specific therapies. Anakinra (IL-1 receptor antagonist) treatment reduces inhaled LPS-induced inflammation in humans. We hypothesize that anakinra treatment will reduce rhinovirus-mediated pro-inflammatory cytokine production from the airway epithelium important for neutrophil recruitment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
